MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1161/circheartfailure.112.972794

Медицинская библиотека · Circulation. Heart failure · 2012

Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial.

Shah Sanjiv J, Heitner John F, Sweitzer Nancy K, Anand Inder S, Kim Hae-Young, Harty Brian, Boineau Robin, Clausell Nadine, Desai Akshay S, Diaz Rafael, Fleg Jerome L, Gordeev Ivan, Lewis Eldrin F, Markov Valetin, O'Meara Eileen, Kobulia Bondo, Shaburishvili Tamaz, Solomon Scott D, Pitt Bertram, Pfeffer Marc A, Li Rebecca

СтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка NIH: внешняя программаПеревод в очереди

Аннотация

BACKGROUND

Treatment of Preserved Cardiac Function with an Aldosterone Antagonist (TOPCAT) is an ongoing randomized controlled trial of spironolactone versus placebo for heart failure with preserved ejection fraction (HFpEF). We sought to describe the baseline clinical characteristics of subjects enrolled in TOPCAT relative to other contemporary observational studies and randomized clinical trials of HFpEF.

METHODS AND

RESULTS

Between August 2006 and January 2012, 3445 patients with symptomatic HFpEF from 270 sites in 6 countries were enrolled in TOPCAT. At the baseline study visit, all subjects provided a detailed medical history and underwent physical examination, electrocardiography, quality of life, and laboratory assessment. Key parameters were compared with other large, contemporary HFpEF studies. The mean age was 68.6±9.6 years with a slight female predominance (52%); mean body mass index was 32 kg/m2; and comorbidities were common. History of hypertension (91% prevalence in TOPCAT) exceeded all other major HFpEF clinical trials. However, baseline blood pressure was well controlled (129/76 mm Hg; systolic blood pressure 7-16 mm Hg lower than other similar trials). Other common comorbidities included coronary artery disease (57%), atrial fibrillation (35%), chronic kidney disease (38%) and diabetes mellitus (32%). Self-reported activity levels were low, quality of life scores were comparable with those reported for patients with end-stage renal disease, and the prevalence of moderate or greater depression was 27%.

CONCLUSIONS

TOPCAT subjects share many common characteristics with contemporary HFpEF cohorts. Low activity level, significantly decreased quality of life, and depression were common at baseline in TOPCAT, underscoring the continued unmet need for evidence-based treatment strategies in HFpEF.

CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. UNIQUE IDENTIFIER: NCT00094302.

Для цитирования: Shah Sanjiv J, Heitner John F, Sweitzer Nancy K, Anand Inder S, Kim Hae-Young, Harty Brian, Boineau Robin, Clausell Nadine, Desai Akshay S, Diaz Rafael, Fleg Jerome L, Gordeev Ivan, Lewis Eldrin F, Markov Valetin, O'Meara Eileen, Kobulia Bondo, Shaburishvili Tamaz, Solomon Scott D, Pitt Bertram, Pfeffer Marc A, Li Rebecca. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial.. Circulation. Heart failure. 2012. DOI: 10.1161/circheartfailure.112.972794.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.